Insider Deck research · News

MRK stock news · Merck & Company, Inc.

Latest Merck & Company, Inc. (MRK) stock news, headlines, and research context on Insider Deck.

News desk

Merck & Company, Inc. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

10 on the wireUpdated within the hour

Simply Wall St.·Wed, Aug 5, 6:09 PM

Merck (MRK) Is Racing Beyond Keytruda As Its Biggest Patent Cliff Nears

Merck (NYSE:MRK) is approaching a major patent cliff for cancer drug Keytruda from 2028. The company is increasing acquisitions and partnerships to broaden its portfolio beyond oncology. Merck is building pipelines in areas such as hematology, infectious diseases, cardiopulmonary, vaccines, and obesity. For investors watching large pharmaceutical companies, Merck sits at an important turning point. Keytruda has been a central product for years, and the upcoming patent expirations put more...

Insider Deck desk note

Last$128.33
Day+0.26%
SymbolMRK

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on Simply Wall St.

Frequently asked questions

What is the latest news on MRK?

The MRK news desk aggregates recent headlines with research context for Merck & Company, Inc..

Where can I research MRK on Insider Deck?

Merck & Company, Inc. (MRK) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.